Document Detail

Assessment of renin dependency of hypertension with a dipeptide renin inhibitor.
MedLine Citation:
PMID:  2188754     Owner:  NLM     Status:  MEDLINE    
To evaluate the participation of the renin-angiotensin system in sustaining hypertension, we administered the specific dipeptide renin inhibitor enalkiren (A-64662) to 18 patients with essential hypertension. Ascending intravenous bolus doses (0.03, 0.1, 0.3, and 1.0 mg/kg) of the inhibitor were each given at 45-minute intervals to patients maintained on an ad libitum sodium diet who were studied while in bed in the semirecumbent posture. Enalkiren produced marked decreases in plasma renin activity (PRA) that were still evident 8 hours after completion of dosing. Systolic and diastolic blood pressures were decreased in a dose-dependent fashion without an effect on heart rate. Repetition of this procedure after patients were subjected to sodium depletion by 1 week of thiazide treatment produced amplified decreases in blood pressure. Despite the short plasma half-life of the inhibitor, these blood pressure-lowering effects were sustained for 4-8 hours when compared with parallel placebo administration in the same patients. Both the baseline PRA and the inhibitor-induced changes in PRA correlated significantly with blood pressure changes during the unstimulated and the sodium-depleted studies. However, effects of the inhibitor on diastolic blood pressure in the latter study correlated most closely with actual increases in renin produced by diuretic pretreatment. Thus, this specific renin inhibitor has demonstrated the dependency of blood pressure on the renin-angiotensin system even during basal conditions in hypertensive patients. Moreover, renin response to sodium depletion appears to be an attribute that additionally characterizes individual hypertensive patients.
M A Weber; J M Neutel; I Essinger; H N Glassman; R S Boger; R Luther
Related Documents :
14504 - Different antihypertensive effect of beta-blocking drugs in low and normal-high renin h...
2825944 - Role of the autonomic nervous system, renin-angiotensin system, and arginine vasopressi...
3905414 - The pharmacokinetics and haemodynamics of bts 49 465 and its major metabolite in health...
8160864 - Renin and vasopressin responses to graded reductions in atrial pressure in conscious dogs.
3335054 - Abnormalities of dynamic ventricular shape change in patients with aortic and mitral va...
3211714 - Deformation of the dog aortic valve ring during the cardiac cycle.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  81     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1990 Jun 
Date Detail:
Created Date:  1990-07-05     Completed Date:  1990-07-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1768-74     Citation Subset:  AIM; IM    
Hypertension Center, Veterans Administration Medical Center, Long Beach, CA 90822.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / blood
Dipeptides / therapeutic use*
Dose-Response Relationship, Drug
Hydrochlorothiazide / therapeutic use
Hypertension / enzymology,  physiopathology*,  therapy
Middle Aged
Renin / antagonists & inhibitors*,  blood
Renin-Angiotensin System / physiology*
Sodium, Dietary / administration & dosage
Reg. No./Substance:
0/Dipeptides; 0/Sodium, Dietary; 113082-98-7/enalkiren; 52-39-1/Aldosterone; 58-93-5/Hydrochlorothiazide; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Grou...
Next Document:  Involvement of endothelin in the regulation of human vascular tonus. Potent vasoconstrictor effect a...